Select Page

Lincoln Pharmaceuticals (Small Cap - Potential Multibagger) Share Target 2026, 2027 To 2035

Lincoln Pharmaceuticals Limited

Company Logo Price: ₹652.95 (2.65%)
52 Week Low: ₹440.00
52 Week High: ₹770.00
Market Capital: 1,224.71 Crore (Small-cap)
Healthcare -> Drug Manufacturers—Specialty & Generic
Show Table of Contents

Lincoln Pharmaceuticals, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 104.6% returns in 5-year showing 8.6% quarterly revenue growth with 16.5% profit margin, making it a potential Multibagger.

To predict the Lincoln Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:

Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices

Approach 1: Technical Analysis Paired With Price Action

Lincoln Pharmaceuticals Share Price Target For 2026

The line chart displays the monthly closing prices of Lincoln Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Lincoln Pharmaceuticals shares in 2026, see the table below.

Lincoln Pharmaceuticals Share Price Target Table For 2026

Level Value Analysis
2026 Target 3 781.29 (+19.65%) Volatility: BB Upper
2026 Target 2 731.04 (+11.95%) Volatility: ATR T1
2026 Target 1 706.29 (+8.16%) Trend: Supertrend Resistance
Current Price 652.95 Lincoln Pharmaceuticals's share price as of 15 Jun 2026
Stop Loss 1 643.94 (-1.38%) 38.20% Weekly Fib Retrace
Stop Loss 2 641.86 (-1.7%) Trend: SMA50
Stop Loss 3 639.05 (-2.13%) Trend: EMA9

Short-Term Technical Outlook

Current Technical Position: Lincoln Pharmaceuticals is showing bullish momentum with price above both 25-day and 50-day moving averages.

Key Technical Level: The 50-day moving average at ₹641.86 serves as the nearest technical reference point.

Historical Returns: 3-month: +11.75% | 6-month: +34.87% | 1-year: +8.56%

Lincoln Pharmaceuticals Share Price Target For 2027

The line chart displays the monthly closing prices of Lincoln Pharmaceuticals with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Lincoln Pharmaceuticals shares in 2027, see the table below.

Lincoln Pharmaceuticals Share Price Target Table For 2027

Level Value Analysis
2027 Target 3 781.29 (+19.65%) Volatility: BB Upper
2027 Target 2 731.04 (+11.95%) Volatility: ATR T1
2027 Target 1 706.29 (+8.16%) Trend: Supertrend Resistance
Current Price 652.95 Lincoln Pharmaceuticals's share price as of 15 Jun 2026
Stop Loss 1 643.94 (-1.38%) 38.20% Weekly Fib Retrace
Stop Loss 2 641.86 (-1.7%) Trend: SMA50
Stop Loss 3 639.05 (-2.13%) Trend: EMA9

Long-Term Technical Outlook

52-Week Range Analysis: Lincoln Pharmaceuticals is currently trading at 64.5% of its 52-week range (₹440 - ₹770).

Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.

Long-Term Performance: 1-year: +8.56% | 3-year: +64.45% | 5-year: +104.57%

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our Telegram channel

Your phone number will be HIDDEN to other users.

Approach 2: Machine Learning By Studying Historical Prices

Lincoln Pharmaceuticals Share Price Target Chart and Table From 2026, 2027, 2028 to 2035

Year Target 1 Target 1 YoY Chg % Target 2
Current Price ₹652.95
2026 ₹723.07 +10.738953978099% ₹733.92
2027 ₹900.05 +24.476191793326% ₹913.55
2028 ₹1,015.04 +12.775956891284% ₹1,030.27
2029 ₹1,135.00 +11.818253467844% ₹1,152.03
2030 ₹1,285.84 +13.28986784141% ₹1,305.13
2031 ₹1,464.06 +13.860200335967% ₹1,486.02
2032 ₹1,756.80 +19.995082168764% ₹1,783.15
2033 ₹2,061.48 +17.342896174863% ₹2,092.40
2034 ₹2,308.16 +11.966160234395% ₹2,342.78
2035 ₹2,557.32 +10.794745598225% ₹2,595.68

Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.

Lincoln Pharmaceuticals Brief Company Overview

Lincoln Pharmaceuticals Limited: A Renowned Pharmaceutical Manufacturer Lincoln Pharmaceuticals Limited, established in 1979, is a leading pharmaceutical manufacturer based in India. The company has a strong global presence, providing a wide range of pharmaceutical... products in various therapeutic areas. Diverse Product Portfolio: Lincoln Pharmaceuticals boasts a comprehensive product range, including cough and cold medications, ophthalmic products, anti-malarial drugs, vitamins and minerals, anti-bacterial, anti-viral, and anti-fungal medications, analgesics, anti-psychotics, cardiovascular drugs, gastrointestinal products, and dermatological preparations. It also offers branded generics. Commitment to Quality: Lincoln Pharmaceuticals is committed to providing high-quality pharmaceutical products. The company has a strong focus on research and development, ensuring its products meet the highest industry standards. Reputation and Innovation: Over the years, Lincoln Pharmaceuticals has established a strong reputation in the pharmaceutical industry. The company is known for its innovation, quality standards, and commitment to patient health. It continues to explore new therapeutic areas and develop innovative products.

Lincoln Pharmaceuticals Financial Performance

Metric Value Description
Market Capital 1,237.63 Crore Market valuation of Lincoln Pharmaceuticals's shares.
Revenue (TTM) 592.21 Crore Total revenue generated by Lincoln Pharmaceuticals over the past twelve months.
Net Income (TTM) +97.96 Crore Net Profit or Loss after all the expenses over the past twelve months.
Operating Margin 13.24% Income from operations as a percentage of revenue, before taxes and interest.
Profit Margin 16.54% Net income as a percentage of revenue, after all expenses.
Revenue Growth
(Quarterly)
+8.6% Change in revenue compared to the previous quarter.
Earnings Growth
(YOY Quarterly)
+24.5% Change in earnings compared to the same quarter last year.
Debt-to-Equity
(D/E) Ratio
0.18 Company's total debt divided by total shareholder equity.
Total Debt 1.06 Crore Sum of Lincoln Pharmaceuticals's current & long-term financial obligations.
Total Cash 152.74 Crore Total amount of liquid funds available to Lincoln Pharmaceuticals.
Beta 0.67 Beta is less than 1 indicating that the Lincoln Pharmaceuticals's price is less volatile than the market.

Is Lincoln Pharmaceuticals A Good Buy For Long Term?

No valid response content found

Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.

All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.